Yamanouchi Pharmaceutical Co., Ltd. And Fujisawa Pharmaceutical Co., Ltd. Unite To Form Astellas Pharma Inc., North American Headquarters To Be In Chicago
10/19/2005 5:13:11 PM
More...
|
Fujisawa Pharmaceutical Co., Ltd. To Outsource Cefzon Bulk Production To API Corporation
10/19/2005 5:13:07 PM
More...
|
Fujisawa Healthcare, Inc. Release: Mycamine(TM) Receives FDA Approval
10/19/2005 5:13:03 PM
More...
|
Gloucester Pharmaceuticals, Inc. Initiates Pivotal Trial With FK228 In Cutaneous T-Cell Lymphoma; FDA Approves Trial Protocol Under Special Protocol Assessment
10/19/2005 5:12:52 PM
More...
|
Merger Mania Besets Japanese Pharmaceuticals
10/19/2005 5:12:49 PM
More...
|
Fujisawa Pharmaceutical Co., Ltd. And Carlsson Research AB Conclude Licensing Agreement For Antipsychotic Agent ACR-16
10/19/2005 5:12:39 PM
More...
|
Cardiome Pharma Corp. (COM.TO) Completes ACT 3 Enrollment
10/19/2005 5:12:08 PM
More...
|
Yamanouchi Pharmaceutical Co., Ltd., Fujisawa Pharmaceutical Co., Ltd. To Become Astellas Post-Merger; $7.12 Billion
10/19/2005 5:11:29 PM
More...
|
Fujisawa Pharmaceutical Co., Ltd. And Yamanouchi Pharmaceutical Co., Ltd. Will Establish Zepharma Inc., An OTC Pharmaceutical Company
10/19/2005 5:11:27 PM
More...
|
Tercica, Inc. Licenses Patent Rights To rhIGF-1 From Fujisawa Pharmaceutical Co., Ltd. In Extreme Insulin Resistance
10/19/2005 5:11:05 PM
More...
|
|